What Does The DEA Removing Epidiolex From The List Of Controlled Substances Mean For The CBD Industry?

At the moment, Epidiolex is the only drug that has been approved by the FDA which is derived directly from cannabis. This means that CBD pharmaceutical Epidiolex is no longer in the country’s list of controlled substances, meaning patients will be able to access it much more easily.

The medication is a CBD-based flavored oral solution that decreases the number of seizures and its severity in children suffering from epilepsy. It is not psychoactive and has less than 0.1% THC. It is produced by GW Pharmaceutical, a drug manufacturer in the UK. The company is also trying to get approval to using Epidiolex for treating seizures linked with other diseases, such as tuberous sclerosis complex.

William Roark is the co-chair of the Pennsylvania Bar Association’s Medical Marijuana and Hemp Law Committee. He believes that this move will make the medicine more accessible to those who need it. Thanks to this move, doctors will not have to go through the drug-monitoring program to see if their patients don’t have a drug history.

In 2018, GW announced that the average annual cost of Epidiolex would come to about $32,500 per year, although most patients with health insurance would pay a fraction of that figure.

Read Full Article: https://hightimes.com

CBD is one of many powerful cannabinoids found in hemp known for helping to support our body and mind. Here at Healing Dragon CBD we do not intend to make unfounded medical claims about the health benefits of CBD. The FDA has not confirmed that CBD cures, treats, or prevents any diseases or conditions. Before reading this article please take a moment to read our full disclosure statement.